These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 38695305)

  • 21. Conversion therapy with an immune checkpoint inhibitor and an antiangiogenic drug for advanced hepatocellular carcinoma: A review.
    Tang H; Cao Y; Jian Y; Li X; Li J; Zhang W; Wan T; Liu Z; Tang W; Lu S
    Biosci Trends; 2022 May; 16(2):130-141. PubMed ID: 35431288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.
    Ku Y; Iwasaki T; Tominaga M; Fukumoto T; Takahashi T; Kido M; Ogata S; Takahashi M; Kuroda Y; Matsumoto S; Obara H
    Ann Surg; 2004 Jan; 239(1):53-60. PubMed ID: 14685100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic treatment of advanced hepatocellular cancer: new hope on the horizon.
    Chang Lee R; Tebbutt N
    Expert Rev Anticancer Ther; 2019 Apr; 19(4):343-353. PubMed ID: 30793991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment.
    Yegin EG; Oymaci E; Karatay E; Coker A
    Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):234-56. PubMed ID: 27298100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma.
    Dhir M; Melin AA; Douaiher J; Lin C; Zhen WK; Hussain SM; Geschwind JF; Doyle MB; Abou-Alfa GK; Are C
    Ann Surg; 2016 Jun; 263(6):1112-25. PubMed ID: 26813914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current status of multimodal & combination therapy for hepatocellular carcinoma.
    Yang J; Yan L; Wang W
    Indian J Med Res; 2012 Sep; 136(3):391-403. PubMed ID: 23041732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the treatment of hepatocellular carcinoma.
    Padhya KT; Marrero JA; Singal AG
    Curr Opin Gastroenterol; 2013 May; 29(3):285-92. PubMed ID: 23507917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic therapeutic strategies for hepatocellular carcinoma: current status and prospects].
    Yuan ZG; Ye SL
    Zhonghua Gan Zang Bing Za Zhi; 2024 Jun; 32(6):565-571. PubMed ID: 38964901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidisciplinary Approach to the Treatment of Advanced Hepatocellular Carcinoma in the Era of New Biologic Agents.
    Shindoh J
    J Nippon Med Sch; 2022 May; 89(2):145-153. PubMed ID: 34840212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventional treatment for unresectable hepatocellular carcinoma.
    Murata S; Mine T; Sugihara F; Yasui D; Yamaguchi H; Ueda T; Onozawa S; Kumita S
    World J Gastroenterol; 2014 Oct; 20(37):13453-65. PubMed ID: 25309076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
    Wang EA; Stein JP; Bellavia RJ; Broadwell SR
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.
    Galle PR; Tovoli F; Foerster F; Wörns MA; Cucchetti A; Bolondi L
    J Hepatol; 2017 Jul; 67(1):173-183. PubMed ID: 28323121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study.
    Liu J; Zhu X; Pan Y; Zhong J; Jin R; Zheng X; Zhang W; Hu K; Ma J; Shi X; Liu H; Yang X; Xu D; Ma C; Chen J; Wang D; Wang X; Li Z; Zhao L; Zhang L; Li T; Liu F; Tan G; Xing B; Zhao H; Zeng Y; Zhang S; Zhang L; Zhou L; Song T; Yang W; Liang X; Xiang B; Xu L; Sun H; Wang K
    Oncologist; 2024 Apr; 29(4):e487-e497. PubMed ID: 37874924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Salvage surgery following downstaging of unresectable hepatocellular carcinoma.
    Lau WY; Ho SK; Yu SC; Lai EC; Liew CT; Leung TW
    Ann Surg; 2004 Aug; 240(2):299-305. PubMed ID: 15273555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook.
    Sahin IH; Khalil L; Millett R; Kaseb A
    Chin Clin Oncol; 2021 Feb; 10(1):7. PubMed ID: 33440948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
    Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
    J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
    Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination treatment including targeted therapy for advanced hepatocellular carcinoma.
    Lin J; Wu L; Bai X; Xie Y; Wang A; Zhang H; Yang X; Wan X; Lu X; Sang X; Zhao H
    Oncotarget; 2016 Oct; 7(43):71036-71051. PubMed ID: 27626176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.